糖尿病是一种威胁全世界的慢性病，其发病率高，影响人们的生活和工作。随着DNA重组技术的发展，长效基础型胰岛素类似物为糖尿病患者带来了希望，其中甘精胰岛素（IGla）、地特胰岛素（IDet）以及德谷胰岛素（IDeg）是临床上常用的3种基础型胰岛素，通过改变结构获得了缓慢的吸收和分布，以及相对较长的作用时间，更符合人体分泌胰岛素的生理模式。对这3种胰岛素制剂在分子结构以及长效作用机制、安全性评价和药效作用方面的研究进展进行总结。

Diabetes is a kind of worldwide chronic disease with high incidence, which threatens people's lives and work. With the development of DNA recombination technology, long-acting basal insulin analogues bring gospel and hope for patients with diabetes. Insulin glargine (IGla), detemir (IDet) and degludec (IDeg), as three basic types of insulin, commonly used in clinical practice that slowly absorbed and distributed by changing the structure, and relatively long acting time, more fit the physiological model of insulin secretion. Therefore, the existing studies of molecular structure, long-acting mechanism, safety evaluation and pharmacodynamic effects of three kinds of insulin preparations are briefly summarized.

国家重点研发计划（2016YFE0121400），国家自然科学基金（81473268）